Greenland Mines Ltd (GRMLW)
NASDAQ: GRMLW · Real-Time Price · USD
0.1382
+0.0522 (60.70%)
Mar 12, 2026, 4:00 PM EDT - Market closed
Company Description
Greenland Mines Ltd develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders.
Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease.
The company was formerly known as Klotho Neurosciences, Inc. and changed its name to Greenland Mines Ltd in March 2026.
Greenland Mines Ltd is based in Omaha, Nebraska.
Greenland Mines Ltd
| Country | United States |
| Employees | 3 |
| CEO | Joseph Sinkule |
Contact Details
Address: 13576 Walnut Street, Suite A Omaha, Nebraska 68144 United States | |
| Phone | 833 931 6330 |
| Website | greenlandmines.com |
Stock Details
| Ticker Symbol | GRMLW |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
Key Executives
| Name | Position |
|---|---|
| Joseph Sinkule | Chief Executive Officer |
| Jeffrey LeBlanc | Chief Financial Officer |